TARDBP and amyotrophic lateral sclerosis: Importantly, CRISPR-iPSC-based disease modeling could expedite research on ALS (Sen and Thummer, 2022) by targeting SOD1 (Kim et al., 2020), TDP-43 (Burkhardt et al., 2013), FUS (Wang et al., 2017), and C9ORF72 (Cali et al., 2019; Ababneh et al., 2020; Krishnan et al., 2020) genes, etc. Furthermore, Strohm et al. (2022) also made CRISPR/Cas9-engineered HeLa cells with ALS UBQLN2 mutations to determine how UBQLN2 mutations cause ALS.